Sakar Healthcare, a manufacturer and exporter specialising in oncology, antibiotics and general formulations, has signed an agreement with Zydus Lifesciences for the supply of oncology products across GCC countries and other emerging markets.
The company has so far signed 40 agreements in the anti-cancer segment globally.
Sakar Healthcare continues to expand its execution capabilities in highly regulated markets through consistent progress in regulatory filings and approvals.
The company has submitted 33 site variations across key partners including Accord Healthcare in the UK, Heumann Pharma GmbH & Co Generica KG in Germany, Torrent Pharma in the UK and Tillomed Laboratories in the UK. These filings cover 18 cytotoxic molecules across major European markets including Germany, Italy, Norway, France, Finland, Sweden, Malta, Romania and the UK.
At present, five site variation approvals have been secured, including 3 from EMA (European Medicines Agency) and 2 from Medicines and Healthcare products Regulatory Agency (MHRA).
Alongside this, Sakar has developed 21 APIs in-house, including 16 with written confirmation and 2 CEP approvals already in place, with additional approvals currently under review.
Sanjay Shah, Managing Director, Sakar Healthcare, said the company is encouraged by the progress in regulatory approvals and API pipeline, supported by multiple approvals and a strong set of applications under review.
“This strengthens our ability to scale operations, enhance market share and deliver meaningful revenue growth in the coming years,” he added.
Published on May 21, 2026